rs747291494
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_022041.4(GAN):c.851+1G>A variant causes a splice donor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000108 in 1,573,746 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_022041.4 splice_donor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GAN | NM_022041.4 | c.851+1G>A | splice_donor_variant | ENST00000648994.2 | NP_071324.1 | |||
GAN | NM_001377486.1 | c.212+1G>A | splice_donor_variant | NP_001364415.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GAN | ENST00000648994.2 | c.851+1G>A | splice_donor_variant | NM_022041.4 | ENSP00000497351 | P1 | ||||
GAN | ENST00000648349.2 | c.*559+1G>A | splice_donor_variant, NMD_transcript_variant | ENSP00000498114 | ||||||
GAN | ENST00000650388.1 | c.*208+1G>A | splice_donor_variant, NMD_transcript_variant | ENSP00000498081 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152206Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000518 AC: 13AN: 250896Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135728
GnomAD4 exome AF: 0.0000113 AC: 16AN: 1421540Hom.: 0 Cov.: 27 AF XY: 0.0000113 AC XY: 8AN XY: 709452
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152206Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74356
ClinVar
Submissions by phenotype
Giant axonal neuropathy 1 Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 22, 2023 | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 246282). Disruption of this splice site has been observed in individuals with clinical features of giant axonal neuropathy (Invitae). This variant is present in population databases (rs747291494, gnomAD 0.03%). For these reasons, this variant has been classified as Pathogenic. This sequence change affects a donor splice site in intron 4 of the GAN gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GAN are known to be pathogenic (PMID: 12655563, 14718689, 23890932). - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 08, 2017 | The c.851+1G>A pathogenic variant in the GAN gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. This variant has been observed in the homozygous state in several unrelated patients referred for genetic testing at GeneDx and not observed in the homozygous state in controls. This splice site variant destroys the canonical splice donor site in intron 4. It is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. The c.851+1G>A variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). This variant is reported as pathogenic in ClinVar, but additional evidence is not available (ClinVar SCV000336956.2, SCV000603804.1; Landrum et al., 2016). We interpret c.851+1G>A as a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Nov 06, 2015 | - - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jan 30, 2017 | - - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 02, 2021 | The c.851+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 4 of the GAN gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at